CellProthera
PrivateLast Round
VC Round
Mar 30, 2023
Total Funding Raised
$22.64M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
CellProthera operates in Healthcare & Life Sciences and is based in Mulhouse. Its latest recorded funding round was a VC Round in March 2023.
CellProthera is a biotechnology company that develops regenerative cell therapy for the structural and functional regeneration of cardiac lesions following a severe heart attack.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware + Subscription, Government Contracts, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CellProthera Comparables
Compare CellProthera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioCardia Inc | 81% | |
| Bayer AG | 73% | |
| Vericel Corporation | 68% |
For institutional investors. Book with your work email.
CellProthera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 30, 2023 | ||||
| Grant | May 1, 2018 | ||||
| VC Round | Sep 3, 2014 | ||||
| Grant | Jul 11, 2013 | ||||
| Seed | Sep 1, 2009 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CellProthera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Union's Horizon Research and Innovation program | Grant |
| Alsace Business Angels | VC Round, Seed |
| SODIV | VC Round |
| Bpifrance | VC Round, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 61% MoM, reaching 1K.
- Jul 20, 2026
Open roles increased to 29, 107% of current headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 11, 2026
CellProthera SAS signs a Memorandum of Understanding with Alfresa Holdings Corporation to establish a strategic collaboration for the development and future distribution of ProtheraCytes in Japan on Aug 11th '26.
For institutional investors. Book with your work email.
CellProthera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CellProthera's valuation, stock price, and market status.
Is CellProthera a public or private company?
CellProthera is a private company.
What is the current stock price of CellProthera?
CellProthera is a private company, so its shares have no public market price. Caplight tracks CellProthera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CellProthera worth (valuation)?
Valuation information for CellProthera is not publicly available.
Can I buy CellProthera stock?
CellProthera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CellProthera's last funding round?
CellProthera's most recent funding round was VC Round on March 30, 2023.
Who are the main investors in CellProthera?
Key investors in CellProthera include Bpifrance.
Will CellProthera IPO soon?
No public IPO plans have been announced for CellProthera.
How can I track CellProthera secondary market activity?
Caplight tracks bids, offers, and trades in CellProthera's shares on secondary markets.